vTv Therapeutics Inc. (VTVT) Balance Sheet

NASDAQ: VTVTAssets, liabilities, debt and equity over 10 years.

VTVT balance sheet, 2025

December 31, 2025 · U.S. dollars

$89.9M assets = $25.5M liabilities + $64.4M equity

What it owns$89.9MCash & ST investments: $88.9M (98.9%)Cash & ST investments$88.9M · 99%Other current: $961,000 (1.1%)Other non-current: $6,000 (0.0%)=How it is financed$89.9MCurrent liabilities: $6.6M (7.4%)Current liabilities $6.6MOther LT liabilities: $18.8M (20.9%)Other LT liabilities$18.8M · 21%Shareholders’ equity: $64.4M (71.7%)Shareholders’ equity$64.4M · 72%

Both columns are drawn to the same scale: what VTVT owns equals what it owes plus shareholders’ equity. Hover a block for its value.

VTVT financial health

Equity / assets71.7%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

VTVT balance sheet trends, 2016–2025

vTv Therapeutics Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$54.5M2016$89.9M2025+5.7%/yr
Total liabilities$145.4M2016$25.5M2025−17.6%/yr
Shareholders’ equity−$90.9M2016$64.4M2025—
Cash & short-term investments$51.5M2016$88.9M2025+6.3%/yr
Total debt$19.4M2016$169,0002024−44.7%/yr
Net cash (debt)$32.1M2016$36.6M2024+$4.5M
Working capital$40.7M2016$83.3M2025+$42.6M
Book value per share−$9.532016$7.652025—
Shares outstanding9.5M20168.4M2025−1.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

VTVT assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

VTVT liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

VTVT debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

VTVT balance sheet

vTv Therapeutics Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$88.9M$36.7M$9.4M$12.1M$13.4M$5.7M$1.8M$1.7M$11.8M$51.5M
Cash & equivalents$88.9M$36.7M$9.4M$12.1M$13.4M$5.7M$1.8M$1.7M$11.8M$51.5M
Short-term investments—$85,000$65,000$15,000$100,000$371,000$250,000$1.1M$162,000$0
Receivables$0$62,000$102,000$12.4M$57,000$158,000$5,000$0$8.0M$0
Inventory$0$0$0$15,000$100,000$371,000$250,000$0$162,000$0
Other current assets$961,000$1.3M$1.1M$2.5M$2.0M$939,000$806,000$1.8M$442,000$612,000
Total current assets$89.9M$38.1M$10.7M$27.1M$15.6M$7.2M$2.8M$3.5M$20.4M$52.1M
Property, plant & equipment (net)$0$153,000$361,000$556,000$680,000$849,000$1.0M$70,000$283,000$444,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$5.6M$9.2M$6.7M$2.5M$2.5M$2.5M$0
Other non-current assets$6,000$0$0$0$0$0$2.9M$2.5M$4.8M$1.9M
Total assets$89.9M$38.3M$11.0M$33.2M$25.5M$14.8M$9.3M$8.6M$27.9M$54.5M
Liabilities
Accounts payable$1.1M$939,000$4.1M$2.5M$1.9M$1.9M$2.2M$2.9M$2.3M$11.4M
Short-term debt—$169,000$360,000$378,000$440,000$239,000$6.3M$9.4M$4.3M$8.4M
Deferred revenue——$17,000$17,000$35,000$31,000$31,000$1.8M$8.8M$21,000
Total current liabilities$6.6M$5.2M$10.6M$7.7M$8.5M$6.4M$13.4M$18.8M$26.9M$11.4M
Long-term debt$0$0$0$0$0$0$0$6.3M$15.3M$11.1M
Lease obligations$0$169,000$338,000$492,000$676,000$831,000$941,000———
Other long-term liabilities$18.8M$18.8M$18.9M$19.7M$1.8M$4.6M$4.7M$66.2M$136.7M$122.9M
Total liabilities$25.5M$24.0M$29.6M$27.4M$10.3M$11.0M$18.1M$91.4M$179.0M$145.4M
Shareholders' equity
Common stock & paid-in capital$39,000$32,000$27,000$27,000$901,000$773,000$641,000$435,000$329,000$329,000
Retained earnings (deficit)−$326.7M−$299.7M−$281.0M−$265.5M−$248.8M−$290.0M−$233.5M−$233.9M−$279.1M−$215.5M
Treasury stock————————$0$0
Accumulated other comprehensive income——————−$148,000−$8.4M−$9.1M−$10.5M
Minority interest$0$2.1M$6.1M$16.6M————$0$0
Total shareholders' equity$64.4M$12.2M−$24.7M−$10.7M−$9.7M−$80.1M−$49.0M−$82.9M−$151.0M−$90.9M
Key figures
Total debt—$169,000$529,000$716,000$932,000$915,000$7.1M$15.7M$19.6M$19.4M
Net cash (debt)—$36.6M$8.9M$11.4M$12.5M$4.8M−$5.3M−$14.0M−$7.8M$32.1M
Working capital$83.3M$32.9M$38,000$19.4M$7.1M$825,000−$10.5M−$15.4M−$6.6M$40.7M
Tangible book value$64.4M$12.2M−$24.7M−$10.7M−$9.7M−$80.1M−$49.0M−$82.9M−$151.0M−$90.9M
Book value per share$7.65$2.11−$11.84−$5.59−$6.22−$67.97———−$9.53
Shares outstanding8.4M5.8M2.1M1.9M1.6M1.2M———9.5M
Current ratio13.547.341.003.521.841.130.210.180.764.56
Quick ratio13.397.080.903.181.590.920.130.090.734.50
Debt / equity—0.01————————
Equity / assets71.7%31.9%−224.0%−32.3%−38.2%−541.6%−529.1%−968.0%−541.1%−166.9%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 10, 2026); data from EODHD.

VTVT financial position

At the end of fiscal 2025 (December 31, 2025), vTv Therapeutics had total assets of $89.9 million (up 134.9% from a year earlier), total liabilities of $25.5 million and shareholders' equity of $64.4 million. Its current ratio was 13.54. In the latest quarter (ended June 30, 2026) total assets were $87.6 million and equity $78.6 million.

Related: VTVT income statement, VTVT cash flow statement, VTVT key metrics. See the VTVT stock overview for the latest quote and news.

VTVT balance sheet FAQ

What are vTv Therapeutics's total assets?

vTv Therapeutics reported total assets of $89.9 million at the end of fiscal 2025 (December 31, 2025), compared with $38.3 million a year earlier.

How much cash does vTv Therapeutics have?

vTv Therapeutics held $88.9 million in cash and short-term investments at the end of fiscal 2025.

What is vTv Therapeutics's book value?

vTv Therapeutics's shareholders' equity (book value) was $64.4 million at the end of fiscal 2025, or $7.65 per share.

What is vTv Therapeutics's current ratio?

vTv Therapeutics had current assets of $89.9 million and current liabilities of $6.6 million, a current ratio of 13.54 (it can cover its short-term obligations).

Biotechnology: balance sheet